Herb Greenberg is a partner at Pacific Square Research, an independent research firm.
Greenberg has been a financial journalist for more than 40 years, working most recently as a commentator at TheStreet.com, senior stocks commentator on CNBC's Business Day programming and on CNBC.com. Earlier, he was co-president of Greenberg Meritz Research & Analytics, and he is a former weekend investor columnist for The Wall Street Journal and a former senior columnist for MarketWatch.
Prior to joining MarketWatch, Greenberg was senior columnist for TheStreet.com. He previously spent 10 years as the Business Insider columnist for the San Francisco Chronicle and nearly seven years as Fortune magazine's monthly Against the Grain columnist.
He also was the New York financial correspondent for the Chicago Tribune and a financial reporter in its Chicago newsroom. Greenberg has held various positions at other media outlets including Crain's Chicago Business and the St. Paul Pioneer Press.
Greenberg holds a bachelor's degree in journalism from the University of Miami.
Follow Herb Greenberg on Twitter @herbgreenberg.
Tesla CEO Elon Musk has always been peculiar, but his behavior during the electric-car maker's quarterly earnings call raises a red flag, says Herb Greenberg, a partner at Pacific Square Research.
Andrew Selepak, University of Florida director of social media masters program, and CNBC Contributor Herb Greenberg discuss comments from former Facebook executive Chamath Palihapitiya's about social media and its impact on society.
Herb Greenberg, Pacific Square Research, discusses General Electric's dividend cut and how this could affect other companies that may want to follow suit.
After Blue Apron and Snap have faltered post-public offering, Herb Greenberg, Pacific Square Research and CNBC contributor, gives his view that some companies should just stay private rather than suffer a disastrous IPO.
CNBC Contributor Herb Greenberg discusses what's causing Herbalife's comeback today.
CNBC's Kate Kelly and CNBC Contributors Ron Insana and Herb Greenberg discuss the ongoing saga between Pershing Square's Bill Ackman and Carl Icahn over Herbalife.
Herb Greenberg, Pacific Square Research Partner, discusses whether or not he believes short sellers are dead.
Elon Musk's Tesla is buying Elon Musk's SolarCity in an all-stock deal worth $2.6 billion, and some Tesla stockholders are not happy about it. CNBC's Phil LeBeau reports. With CNBC Contributor Herb Greenberg.
Eric Schurenberg, Inc. Media president, and Herb Greenberg, Pacific Square Research, discuss their take on companies staying private versus going public.